Study to Evaluate Safety Tolerability Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

STATUS

Recruiting
participants needed

36
sponsor

Akros Pharma Inc.

Send

Updated on 19 February 2024

See if I qualify

body mass index

plasma glucose

fasting

metformin

Summary

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JTT-662 administered once daily for 28 days in subjects with Type 2 diabetes mellitus (T2DM) who are receiving metformin monotherapy

Details

Condition	NIDDM, diabetes mellitus, type 2, diabetes mellitus, type 2
Age	18years - 65years
Treatment	Placebo, JTT-662
Clinical Study Identifier	NCT04465877
Sponsor	Akros Pharma Inc.
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Diagnosis of T2DM for at least 12 weeks prior to the Screening Visit
	Currently treated with a stable oral dose of metformin for at least 12 weeks prior to the Screening Visit
	Have a glycosylated hemoglobin (HbA1c) value of between 6.5% and 10.0% at the Screening Visit
	Have a fasting plasma glucose (FPG) value of no more than 280 mg/dL at the Screening Visit and on Day -3
	Body Mass Index (BMI) of 25 to 40 kg/m2 (inclusive)
	Must be willing to wear a continuous glucose monitor (CGM) device
Exclusion Criteria
	Known medical history or presence of Type 1 diabetes mellitus, Maturity Onset Diabetes of the Young or secondary forms of diabetes
	Known medical history or presence of diabetic complications
	Have taken anti-diabetic medications (other than metformin) or medications that act mainly in the gastrointestinal tract (e.g., orlistat, acarbose) within 12 weeks prior to the Screening Visit or from the Screening Visit to Day -3
	Have uncontrolled hypertension (systolic blood pressure of at least 160 mmHg or diastolic blood pressure of at least 95 mmHg) at the Screening Visit
	Have impaired renal function (estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2)

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Study to Evaluate Safety Tolerability Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes